A company called Compass Pathways (ticker: CMPS) is running a large late-stage clinical trial on a psilocybin-based treatment, and the results are expected in 2026. When a speculative biotech company releases make-or-break trial data, its stock price tends to jump or crash dramatically in a single day. Good news could send the stock soaring; bad news could wipe out a quarter or more of its value overnight.
A binary clinical catalyst on a heavily-positioned, speculative biotech name reliably produces violent single-day repricing in either direction. Both supporting agents converge on this magnitude.
Join our community — a free weekly Zoom circle with a master facilitator. Come sit with us first; the rest reveals itself.
Join the Free Weekly Circle →